Studies Make Case for Hormonal Therapy in nmCRPC

]]>(MedPage Today) -- Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) lived significantly longer if they received an androgen signaling inhibitor (ASI) in addition to conventional androgen deprivation therapy (ADT), three large...